



# The total synthesis and biological evaluation of nafuredin- $\gamma$ and its analogues

Tohru Nagamitsu<sup>a</sup>, Daisuke Takano<sup>a</sup>, Miyuki Seki<sup>a</sup>, Shiho Arima<sup>a</sup>, Masaki Ohtawa<sup>a</sup>, Kazuro Shiomi<sup>b</sup>, Yoshihiro Harigaya<sup>a</sup>, Satoshi Ōmura<sup>b,\*</sup>

<sup>a</sup>School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan

<sup>b</sup>Kitasato Institute for Life Sciences and Graduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan

## ARTICLE INFO

### Article history:

Received 27 February 2008

Received in revised form 17 June 2008

Accepted 17 June 2008

Available online 21 June 2008

## ABSTRACT

Nafuredin (**1**) is converted to nafuredin- $\gamma$  (**2**) under mild basic conditions and both compounds exhibit the same inhibitory activity and selectivity against NADH-fumarate reductase (complex I). The total synthesis of **2** was achieved by a convergent approach using Stille coupling. The structural elements required for inhibitory activity against NADH-fumarate reductase (complex I) were then investigated by evaluation of nafuredin- $\gamma$  (**2**) and its structural analogues.


© 2008 Elsevier Ltd. All rights reserved.

## 1. Introduction

Nafuredin (**1**)<sup>1,2</sup> was isolated from the fermentation broth of a fungal strain, *Aspergillus niger* FT-0554, in the course of our screening for NADH-fumarate reductase (NFRD) inhibitors, and is potentially a selective antiparasitic agent. Nafuredin inhibited NFRD of *Ascaris suum* with an IC<sub>50</sub> value of 12 nM and showed selective inhibition of the target enzyme complex I in helminth mitochondria. In addition, nafuredin demonstrated anthelmintic activity against *Haemonchus contortus* in vivo trials with sheep.<sup>1</sup> These useful biological activities of **1** attracted our attention, and

we previously reported the elucidation of the absolute configuration<sup>3</sup> and the total synthesis<sup>4</sup> of **1**.

During the course of our synthetic studies, we discovered that under mild basic conditions, nafuredin (**1**) was converted to a novel  $\gamma$ -lactone derivative (**2**), which existed as a mixture of keto–enol tautomers (Scheme 1).<sup>5</sup> We named this  $\gamma$ -lactone derivative (**2**) nafuredin- $\gamma$ . Since nafuredin- $\gamma$  (**2**) is not detected at all in the aforementioned fermentation broth, it must not be produced directly by the above strain and must be formed from **1** under basic conditions via  $\beta$ -elimination of the epoxide followed by trans-lactonization. Because the conversion of **1** to **2** likely occurs under



**Scheme 1.** Proposed mechanism of the conversion of nafuredin (**1**) to nafuredin- $\gamma$  (**2**).

\* Corresponding author. Tel.: +81 3 5791 6101; fax: +81 3 3444 8360.

E-mail address: [omura-s@kitasato.or.jp](mailto:omura-s@kitasato.or.jp) (S. Ōmura).

the NFRD assay conditions, we expected **2** to also have inhibitory activity against NFRD. Our tests indeed showed that **2** possessed the same inhibitory activity and selectivity as **1**, suggesting it may be an active form of **1**. This finding led us to embark on the total synthesis of nufuredin- $\gamma$  (**2**)<sup>6</sup> and allowed structural simplification of the lactone moiety in the structure–activity relationship studies of **1**. We provide herein a detailed account of the total synthesis and the structure–activity relationship studies of nufuredin- $\gamma$  (**2**).


## 2. Results and discussion

### 2.1. Total synthesis of nufuredin- $\gamma$ (**2**)

As outlined in Scheme 2, our retrosynthetic strategy toward nufuredin- $\gamma$  (**2**) is convergent and involves the assembly of the C1–C7 segment **3** and the C8–C18 segment **4**, which will be joined in the final step by Stille coupling. This route provides a simple and efficient method to synthesize various nufuredin- $\gamma$  analogues with modifications of the side chain moiety and also promises to be especially effective for the synthesis of C4 and/or C5 stereoisomers of nufuredin- $\gamma$  (**2**). The enol lactone **3** will be constructed by Horner–Wadsworth–Emmons reaction of aldehyde **5** with known phosphonate **6** followed by hydrostannylation. The aldehyde **5** will

cyclopentanone in the presence of a catalytic amount of TsOH in benzene caused serious racemization by transesterification of the *p*-methoxybenzoyl ester. However, treatment with cyclopentanone dimethylacetal in the presence of Sc(OTf)<sub>3</sub> catalyst<sup>11</sup> gave **9** almost quantitatively without loss of stereochemical integrity. Cleavage of the *p*-methoxybenzoyl ester with sodium methoxide in methanol produced **10** in 97% yield. Oxidation of **10** with Dess–Martin periodinane<sup>12</sup> followed by Wittig reaction with methyl (triphenylphosphoranylidene)acetate furnished **11** in 75% yield over 2 steps. The resulting ester was reduced with DIBAL to give allyl alcohol **12** in 94% yield. Sharpless asymmetric epoxidation of **12** using (+)-diethyl tartrate provided the corresponding epoxide (94% de), which was then converted to chloride **7** by treatment with NCS and Ph<sub>3</sub>P in the presence of an excess amount of 2-methyloxirane as a chloride ion scavenger in 94% yield over 2 steps. This reaction in the absence of 2-methyloxirane gave a mixture of undesired products formed by addition of chloride ion to the epoxide. Base-induced elimination<sup>13</sup> of **7** with *n*-BuLi furnished **13** in 99% yield. Silyl ether protection of **13** with TBSOTf and 2,6-lutidine followed by hydrolysis of the cyclopentylidene acetal with 70% aqueous AcOH led to diol **14** in 87% yield over 2 steps.

Oxidation of the primary alcohol in **14** with 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) and trichloroisocyanuric acid<sup>14</sup>




Scheme 2. Retrosynthesis of nufuredin- $\gamma$  (**2**).


be derived from the epoxy chloride **7**, which will be constructed by Sharpless asymmetric epoxidation<sup>8</sup> and dihydroxylation<sup>9</sup> as key reactions.

The known diol **8** (97% ee)<sup>10</sup> was used as the precursor to aldehyde **5** as shown in Scheme 3. Acetalization of **8** with

gave the desired aldehyde **5** (Scheme 4), while DMSO oxidation (Swern conditions and Parikh–Doering conditions), Dess–Martin oxidation, and TEMPO–NaClO–KBr oxidation caused decomposition of the product. The use of trichloroisocyanuric acid as a co-oxidant in the TEMPO oxidation of **14** was crucial for high yield




Scheme 3. Reagents and conditions: (a) cat. Sc(OTf)<sub>3</sub>, 1,1-dimethoxycyclopentane, MeCN, rt, 99%; (b) NaOMe, MeOH, rt, 97%; (c) Dess–Martin periodinane, CH<sub>2</sub>Cl<sub>2</sub>, rt; (d) Ph<sub>3</sub>P=CHCO<sub>2</sub>Me, benzene, reflux, 75% (2 steps); (e) DIBAL, CH<sub>2</sub>Cl<sub>2</sub>, –78 °C, 94%; (f) (+)-DET, Ti(Oi-Pr)<sub>4</sub>, TBHP, CH<sub>2</sub>Cl<sub>2</sub>, –20 °C; (g) NCS, PPh<sub>3</sub>, 2-methyloxirane, CH<sub>2</sub>Cl<sub>2</sub>, rt, 94% (2 steps); (h) *n*-BuLi, THF, –40 °C, 99%; (i) TBSOTf, 2,6-lutidine, CH<sub>2</sub>Cl<sub>2</sub>, rt; (j) 70% aq AcOH, rt, 87% (2 steps).



**Scheme 4.** Reagents and conditions: (a) cat. TEMPO, trichloroisocyanuric acid,  $\text{CH}_2\text{Cl}_2$ ,  $0^\circ\text{C}$ ; (b) **6**, DBU, LiCl, MeCN,  $0^\circ\text{C}$ , 75% (2 steps); (c) HF·pyridine, THF, rt, 91%; (d)  $\text{Bu}_3\text{SnH}$ , cat.  $\text{PdCl}_2(\text{PPh}_3)_2$ , THF,  $0^\circ\text{C}$ ; (e) **4**, cat.  $\text{PdCl}_2(\text{MeCN})_2$ , NMP,  $50^\circ\text{C}$ , 72%; (f) **4**, cat.  $\text{PdCl}_2(\text{MeCN})_2$ , NMP,  $\text{Ph}_2\text{P}(\text{O})\text{O}^-\text{Bu}_4\text{N}^+$ ,  $50^\circ\text{C}$ , 63%; (g) HF·pyridine, THF, rt, 85%.

and reproducibility. Aldehyde **5** was subjected to the next reaction without further purification because of its instability. Horner–Wadsworth–Emmons reaction of **5** with the known phosphonate **6**<sup>7</sup> in the presence of DBU and LiCl<sup>15</sup> afforded  $\gamma$ -lactone **15** in 75% yield over 2 steps.  $\gamma$ -Lactone **15** was treated with HF·pyridine to give **16** in 91% yield. Subsequent palladium-catalyzed hydrostannylation<sup>16</sup> of **16** with  $\text{Bu}_3\text{SnH}$  and  $\text{PdCl}_2(\text{PPh}_3)_2$  proceeded nonregioselectively, yielding the desired *E*-alkenylstannane **3** (39%) and its regioisomer **17** (30%). After separation by silica gel chromatography, Stille coupling<sup>17</sup> between **3** and vinyl iodide **4** in the presence of  $\text{PdCl}_2(\text{MeCN})_2$  gave nafuredin- $\gamma$  (**2**) in 72% yield.

Next, we focused on the high regioselectivity of palladium-catalyzed hydrostannylation of alkynyl bromides reported by Guibé et al.<sup>19</sup> Bromination of the terminal alkynes **15** and **16** led to decomposition of the substrates. Therefore, TBS protected enol ether **20** was constructed by oxidation of **14** followed by Horner–Wadsworth–Emmons reaction with **6** and LHMDS (75% yield, 2 steps). Enol ether **20** afforded alkynyl bromide **21** quantitatively upon treatment with NBS and  $\text{AgNO}_3$ <sup>20</sup> (Scheme 5). Removal of the TBS ether group with HF·pyridine gave enol **22** quantitatively. Subsequent palladium-catalyzed hydrostannylation of **22** provided the desired *E*-alkenylstannane **3** in 71% yield with high regioselectivity



**Scheme 5.** Reagents and conditions: (a) cat. TEMPO, trichloroisocyanuric acid,  $\text{CH}_2\text{Cl}_2$ ,  $0^\circ\text{C}$ ; (b) **6**, LHMDS, THF,  $0^\circ\text{C}$ , 75% (2 steps); (c) cat.  $\text{AgNO}_3$ , NBS, acetone, rt, 100%; (d) HF·pyridine, THF, rt, 100%; (e)  $\text{Bu}_3\text{SnH}$ , cat.  $\text{PdCl}_2(\text{PPh}_3)_2$ , THF,  $0^\circ\text{C}$ , 71%; (f) **4**, cat.  $\text{PdCl}_2(\text{MeCN})_2$ , NMP,  $50^\circ\text{C}$ , 72%.

Although the total synthesis of **2** was achieved, a more effective hydrostannylation procedure with higher regioselectivity was required for large-scale synthesis of **2**. We therefore examined hydrostannylation of the TBS ether **15**, which provided **18** in 52% yield along with its regioisomer **19** (23%). However, subsequent Stille coupling of **18** with **4** did not proceed well under the same conditions (20% yield). Addition of  $\text{Ph}_2\text{P}(\text{O})\text{O}^-\text{Bu}_4\text{N}^+$ <sup>18</sup> improved the yield of the coupled product (63%), affording nafuredin- $\gamma$  (**2**) in 85% yield after removal of the TBS ether group with HF·pyridine. Unfortunately, these moderate yields in hydrostannylation and Stille coupling were still far from satisfactory.

(**3**/**17**=15:1). This was converted to nafuredin- $\gamma$  (**2**) in good yield as mentioned above. Synthetic nafuredin- $\gamma$  (**2**) was identical to that derived from natural nafuredin (**1**) in all respects ([ $\alpha$ ]<sub>D</sub>,  $^1\text{H}$  and  $^{13}\text{C}$  NMR, IR, FABMS, and inhibitory activity against NFRD).

## 2.2. Synthesis of analogues of nafuredin- $\gamma$ (**2**)

Our continued efforts on the structure–activity relationships of **2** led to the synthesis of new analogues **23–25** (Fig. 1) using our strategy for the total synthesis of nafuredin- $\gamma$ .<sup>6</sup> These new nafuredin- $\gamma$  analogues are the C4-epimer (**23**), the C5-epimer (**24**), and




Figure 1. Chemical structures of nafuredin- $\gamma$  (**2**) and new nafuredin- $\gamma$  analogues (**23–25**).

the 2-dehydroxy- $\alpha,\beta$ -unsaturated lactone (**25**). These analogues were selected in order to elucidate the requirements of the C4 and C5 stereochemistries and the enol in **2** for inhibitory activity against NADH-fumarate reductase (complex I).

The synthesis of the C4-epimer (**23**) started from methallyl alcohol, which was readily converted into the chiral diol **26**<sup>10</sup> (97% ee) through asymmetric dihydroxylation (Scheme 6). The  $\text{Sc}(\text{OTf})_3$ -catalyzed acetalization of **26** followed by cleavage of the *p*-methoxybenzoyl ester with sodium methoxide furnished alcohol **27**. Subsequent Dess–Martin oxidation and Wittig reaction afforded the corresponding  $\alpha,\beta$ -unsaturated ester, which was reduced with DIBAL to give allyl alcohol **28**. Sharpless asymmetric epoxidation of **28** using (+)-diethyl tartrate provided the corresponding epoxy alcohol, which was further converted to chloride **29** by treatment with NCS and  $\text{Ph}_3\text{P}$  in the presence of 2-methyloxirane. Base-induced elimination of **29** with *n*-BuLi propargyl alcohol **30**. A two-step sequence of protecting group manipulations provided diol **31**. Oxidation of the primary alcohol in **31** with TEMPO gave the corresponding aldehyde, which was subjected to Horner–Wadsworth–Emmons reaction using **6**, followed by deprotection of the silyl ethers to produce 2-hydroxy- $\alpha,\beta$ -unsaturated lactone **32**. After the enol of **32** was protected as a TBDPS ether to facilitate handling and NMR assignment of the substrate, hydrostannylation afforded the desired *E*-alkenylstannane **33** as the major product. Stille coupling with the vinyl iodide **4** in the presence of a catalytic


amount of  $\text{PdCl}_2(\text{MeCN})_2$  and subsequent deprotection of the silyl enol ether gave the desired C4-epimer (**23**).

We next synthesized the C5-epimer (**24**) as shown in Scheme 7. Allyl alcohol **12**, an advanced intermediate in the total synthesis of **2**, was converted into chloride **34** by Sharpless asymmetric epoxidation using (–)-diethyl tartrate followed by chlorination of the resulting epoxy alcohol. Further transformations from the chloride **34** to the C5-epimer (**24**) were achieved in the same manner as the synthesis of **23**.


Finally, we investigated the synthesis of the 2-dehydroxy- $\alpha,\beta$ -unsaturated lactone (**25**) (Scheme 8). Diol **14** was oxidized with TEMPO to furnish the corresponding aldehyde, which was subjected to Still–Gennari olefination<sup>21</sup> followed by deprotection of the silyl ether to give  $\alpha,\beta$ -unsaturated lactone **39**. Hydrostannylation of **39** led to the desired *E*-alkenylstannane **40**. Stille coupling between **40** and the vinyl iodide **4** in the presence of a catalytic amount of  $\text{PdCl}_2(\text{MeCN})_2$  gave the desired 2-dehydroxy- $\alpha,\beta$ -unsaturated lactone (**25**). Although the regioselectivities and yields of several reactions in the synthesis of nafuredin- $\gamma$  analogues were unsatisfactory, priority was given to their biological evaluation.

### 2.3. Biological evaluation of the new nafuredin- $\gamma$ analogues


With the nafuredin- $\gamma$  analogues **23–25** in hand, the inhibitory activity against NFRD of *A. suum* was evaluated and the results are



Scheme 6. Reagents and conditions: (a)  $\text{PMBzCl}$ ,  $\text{Et}_3\text{N}$ , cat. DMAP,  $\text{CH}_2\text{Cl}_2$ , rt, quant.; (b)  $(\text{DHQ})_2\text{PHAL}$ ,  $\text{K}_2\text{OsO}_4 \cdot 2\text{H}_2\text{O}$ ,  $\text{K}_3\text{Fe}(\text{CN})_6$ ,  $\text{K}_2\text{CO}_3$ ,  $t\text{-BuOH}/\text{H}_2\text{O}$ ,  $0^\circ\text{C}$ , 95%; (c) cat.  $\text{Sc}(\text{OTf})_3$ , 1,1-dimethoxycyclopentane, MeCN, rt, 84%; (d) NaOMe, MeOH, rt, 73%; (e) Dess–Martin periodinane,  $\text{CH}_2\text{Cl}_2$ , rt; (f)  $\text{Ph}_3\text{P}=\text{CHCO}_2\text{Et}$ , benzene,  $80^\circ\text{C}$ , 75% (2 steps); (g) DIBAL,  $\text{CH}_2\text{Cl}_2$ ,  $-78^\circ\text{C}$ , 82%; (h) (+)-DET,  $\text{Ti}(\text{Oi-Pr})_4$ , TBHP,  $\text{CH}_2\text{Cl}_2$ ,  $-20^\circ\text{C}$ ; (i) NCS,  $\text{PPh}_3$ , 2-methyloxirane,  $\text{CH}_2\text{Cl}_2$ , rt, 86% (2 steps); (j) *n*-BuLi, THF,  $-40^\circ\text{C}$ , 99%; (k) TBSOTf, 2,6-lutidine,  $\text{CH}_2\text{Cl}_2$ ,  $0^\circ\text{C}$ , 99%; (l) 70% aq AcOH, rt, 78%; (m) cat. TEMPO, trichloroisocyanuric acid,  $\text{CH}_2\text{Cl}_2$ ,  $0^\circ\text{C}$ ; (n) LHMDS, **6**, THF,  $-78^\circ\text{C}$ ; (o) HF·pyridine, THF, rt, 52% (3 steps); (p) TBDPSCl,  $\text{Et}_3\text{N}$ , THF, rt, 56%; (q) cat.  $\text{PdCl}_2(\text{PPh}_3)_2$ ,  $\text{Bu}_3\text{SnH}$ , THF,  $0^\circ\text{C}$ , 47%; (r) cat.  $\text{PdCl}_2(\text{MeCN})_2$ , **4**, NMP,  $50^\circ\text{C}$ , 32%; (s) HF·pyridine, THF, rt, 85%.



**Scheme 7.** Reagents and conditions: (a) (–)-DET, Ti(Oi-Pr)<sub>4</sub>, TBHP, CH<sub>2</sub>Cl<sub>2</sub>, –20 °C; (b) NCS, PPh<sub>3</sub>, 2-methyloxirane, CH<sub>2</sub>Cl<sub>2</sub>, rt, 92% (2 steps); (c) *n*-BuLi, THF, –40 °C, 97%; (d) TBSOTf, 2,6-lutidine, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 96%; (e) AcOH, rt, 86%; (f) cat. TEMPO, trichloroisocyanuric acid, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (g) LHMDS, **6**, THF, –78 °C; (h) HF·pyridine, THF, rt, 49% (3 steps); (i) TBDPSCl, Et<sub>3</sub>N, THF, rt, 65%; (j) cat. PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, Bu<sub>3</sub>SnH, THF, 0 °C, 73%; (k) cat. PdCl<sub>2</sub>(MeCN)<sub>2</sub>, **4**, NMP, 50 °C, 28%; (l) HF·pyridine, THF, rt, 84%.



**Scheme 8.** Reagents and conditions: (a) cat. TEMPO, trichloroisocyanuric acid, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (b) LHMDS, (CF<sub>3</sub>CH<sub>2</sub>O)<sub>2</sub>P(O)CH<sub>2</sub>CO<sub>2</sub>Me, THF, 0 °C; (c) HF·pyridine, THF, rt, 55% (3 steps); (d) cat. PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, Bu<sub>3</sub>SnH, THF, rt, 68%; (e) cat. PdCl<sub>2</sub>(MeCN)<sub>2</sub>, **4**, NMP, 50 °C, 70%.

**Table 1**  
Inhibitory activity of the nafuredin-γ analogues against NFRD of *Ascaris suum*

Compound	IC <sub>50</sub> (nM)
Nafuredin-γ ( <b>2</b> )	6
<b>23</b>	7
<b>24</b>	120
<b>25</b>	8

summarized in Table 1. Surprisingly, both the IC<sub>50</sub> values of the C4-epimer (**23**) and the 2-dehydroxy-α,β-unsaturated lactone (**25**) were nearly identical to that of nafuredin-γ (**2**). However, NFRD inhibitory activity of the C5-epimer (**24**) decreased more than ten times. Therefore, it was concluded that the stereochemistry at C4 and the presence of the enol (or 2-ketone) are not important, but the C5 stereochemistry is valuable for the inhibitory activity against NADH-fumarate reductase (complex I).

### 3. Summary

We have discovered nafuredin-γ (**2**), a proposed active form of nafuredin (**1**), and achieved its first total synthesis. This enabled construction of the diverse nafuredin-γ analogues **23–25**. The structure–activity relationship studies of **2** revealed that the C4 stereochemistry and the enol (or 2-ketone) functionality as structural elements are not required as structural elements, but the stereochemistry of the C5 hydroxy group is important for the NFRD

inhibitory activity of **2**. These results will allow further structural simplification of the lactone moiety and lead to the development of shorter and more efficient syntheses for new nafuredin-γ analogues. Additional structure–activity relationship studies of **2** are in progress and will be reported in due course.

## 4. Experimental

### 4.1. General information

Commercial reagents were used without further purification unless otherwise indicated. Organic solvents were distilled and dried over 3 Å or 4 Å molecular sieves. Reactions were performed in flame-dried glassware under positive Ar pressure unless otherwise indicated. Cold baths were generated as follows: 0 °C, wet ice/water; –78 °C, dry ice/acetone. Flash chromatography was performed on silica gel 60 N (spherical, neutral, particle size 40–50 μm). TLC was performed on 0.25 mm E. Merck silica gel 60 F<sub>254</sub> plates and visualized by UV light (254 nm) and cerium ammonium molybdenate.

### 4.2. Conversion of nafuredin (**1**) to nafuredin-γ (**2**)

Compound **1** (10.0 mg) was dissolved in MeOH (0.28 mL), and CaCO<sub>3</sub> (2.0 mg) was added to the solution. After the solution was stirred at room temperature for 30 min, EtOAc (10 mL) and a saturated aqueous NaCl solution (10 mL) were added. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated to yield **2**<sup>5</sup> (9.3 mg, 93%).

### 4.3. Total synthesis of nafuredin-γ (**2**)

#### 4.3.1. (S)-(2-Methyl-1,4-dioxaspiro[4.4]nonan-2-yl)methyl 4-methoxybenzoate (**9**)

To a solution of **8** (1.75 g, 7.29 mmol) in MeCN (70 mL) were added 1,1-dimethoxycyclopentane (2.00 mL, 14.5 mmol) and Sc(OTf)<sub>3</sub> (31.3 mg, 72.9 μmol) at room temperature. The resulting solution was stirred for 1 h and diluted with a saturated aqueous NaHCO<sub>3</sub> solution. The aqueous phase was extracted with EtOAc. The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. Flash chromatography (30:1 hexanes/EtOAc) afforded **9** (2.21 g, 99%) as a colorless oil. [α]<sub>D</sub><sup>23</sup> +2.8 (c 1.0, CHCl<sub>3</sub>); IR (KBr) 2953, 2733, 1770, 1558, 1157, 1110 cm<sup>–1</sup>; <sup>1</sup>H NMR (270 MHz, CDCl<sub>3</sub>) δ 7.99 (d, 2H, J=8.9 Hz), 6.91 (d, 2H, J=8.7 Hz), 4.25 (d, 1H, J=11.2 Hz), 4.17 (d, 1H, J=11.2 Hz), 4.02 (d, 1H, J=8.6 Hz), 3.84 (s, 3H), 3.67 (d, 1H, J=8.6 Hz), 1.76 (m, 8H), 1.38 (s, 3H); <sup>13</sup>C NMR (67.5 MHz, CDCl<sub>3</sub>) δ 165.9, 163.4, 131.6, 122.3, 119.7, 113.6, 78.9,

71.8, 67.8, 55.3, 37.3, 37.1, 23.6, 23.3, 22.2; HRMS (FAB, *m*-NBA)  $M^+$  calcd for  $C_{17}H_{22}O_5$ : 306.1467, found: 306.1465.

#### 4.3.2. (*R*)-(2-Methyl-1,4-dioxaspiro[4.4]nonan-2-yl)methanol (**10**)

To a stirred solution of **9** (1.87 g, 6.11 mmol) in MeOH (20 mL) was added NaH (60% in oil, 49.8 mg, 1.22 mmol). The resulting solution was stirred for 45 min at room temperature, diluted with  $H_2O$ , and extracted with EtOAc. The combined organic extracts were dried over anhydrous  $Na_2SO_4$  and concentrated in vacuo. Flash chromatography (5:1 hexanes/EtOAc) afforded **10** (1.02 g, 97%) as a colorless oil.  $[\alpha]_D^{25} +5.0$  (c 1.0,  $CHCl_3$ ); IR (KBr) 3327, 2732, 1234, 1103, 1024  $cm^{-1}$ ;  $^1H$  NMR (270 MHz,  $CDCl_3$ )  $\delta$  3.88 (d, 1H,  $J=8.6$  Hz), 3.59 (d, 1H,  $J=8.6$  Hz), 3.45 (m, 2H), 2.26 (br s, 1H), 1.75 (m, 8H), 1.32 (s, 3H);  $^{13}C$  NMR (67.5 MHz,  $CDCl_3$ )  $\delta$  119.3, 80.7, 71.1, 66.9, 37.1, 23.5, 23.1, 21.7; HRMS (FAB, *m*-NBA)  $M^+$  calcd for  $C_9H_{16}O_3$ : 172.1099, found: 172.1103.

#### 4.3.3. (*R,E*)-Methyl 3-(2-methyl-1,4-dioxaspiro[4.4]nonan-2-yl)acrylate (**11**)

To a solution of **10** (762 mg, 4.43 mmol) in  $CH_2Cl_2$  (45 mL) was added Dess–Martin periodinane (2.40 g, 5.76 mmol) at room temperature. After 1 h, the reaction was quenched with saturated aqueous solutions of  $Na_2S_2O_3$  and  $NaHCO_3$  and extracted with  $CH_2Cl_2$ . The combined organic extracts were dried over anhydrous  $Na_2SO_4$  and concentrated in vacuo. This residue was employed in the next reaction without further purification.

To a solution of the resulting aldehyde in benzene (45 mL) was added (carbomethoxymethylene)triphenylphosphorane (2.2 g, 6.64 mmol). The reaction was refluxed for 1 h and concentrated in vacuo. Flash chromatography (20:1 hexanes/EtOAc) afforded **11** (751 mg, 75% for 2 steps) as a yellow oil.  $[\alpha]_D^{25} -54.0$  (c 0.1,  $CHCl_3$ ); IR (KBr) 2973, 2871, 1726, 1662, 1303, 1170, 1105  $cm^{-1}$ ;  $^1H$  NMR (270 MHz,  $CDCl_3$ )  $\delta$  6.95 (d, 1H,  $J=15.5$  Hz), 6.07 (d, 1H,  $J=15.5$  Hz), 3.84 (d, 1H,  $J=8.2$  Hz), 3.76 (d, 1H,  $J=8.2$  Hz), 3.74 (s, 3H), 1.76 (m, 8H), 1.40 (s, 3H);  $^{13}C$  NMR (67.5 MHz,  $CDCl_3$ )  $\delta$  166.8, 150.5, 120.1, 119.6, 79.6, 74.0, 51.6, 37.0, 36.8, 24.4, 23.4, 23.3; HRMS (FAB, *m*-NBA)  $[M+H]^+$  calcd for  $C_{12}H_{19}O_4$ : 227.1283, found: 227.1272.

#### 4.3.4. (*R,E*)-3-(2-Methyl-1,4-dioxaspiro[4.4]nonan-2-yl)prop-2-en-1-ol (**12**)

To a solution of **11** (1.66 g, 7.35 mmol) in  $CH_2Cl_2$  (70 mL) was added dropwise DIBAL (1.0 M solution in hexane, 22 mL, 22.0 mmol) at  $-78^\circ C$ . After stirring for 0.5 h, the reaction mixture was quenched with MeOH, diluted with  $CH_2Cl_2$ , and treated with Celite (20 g) and  $Na_2SO_4 \cdot 10H_2O$  (20 g). The resulting mixture was stirred for 2 h at room temperature and then filtered through a pad of Celite. The filtrates were concentrated in vacuo. The residue was purified by column chromatography (3:1 hexanes/EtOAc) to give **12** (1.37 g, 94%) as a colorless oil.  $[\alpha]_D^{25} -6.0$  (c 1.0,  $CHCl_3$ ); IR (KBr) 3428, 2973, 2871, 1334, 1106, 975  $cm^{-1}$ ;  $^1H$  NMR (270 MHz,  $CDCl_3$ )  $\delta$  5.91 (dt, 1H,  $J=15.5, 4.9$  Hz), 5.79 (d, 1H,  $J=15.5$  Hz), 4.17 (t, 2H,  $J=4.9$  Hz), 3.77 (d, 1H,  $J=8.2$  Hz), 3.72 (d, 1H,  $J=8.2$  Hz), 1.75 (m, 8H), 1.37 (s, 3H);  $^{13}C$  NMR (67.5 MHz,  $CDCl_3$ )  $\delta$  143.3, 128.5, 119.5, 79.6, 74.6, 62.7, 37.2, 37.0, 24.4, 23.3; HRMS (FAB, *m*-NBA)  $M^+$  calcd for  $C_{11}H_{18}O_3$ : 198.1256, found: 198.1254.

#### 4.3.5. (*S*)-2-[(2*R*,3*R*)-3-(Chloromethyl)oxiran-2-yl]-2-methyl-1,4-dioxaspiro[4.4]nonane (**7**)

To a mixture of MS 4 Å (3.00 g) and (+)-DET (1.70 mL, 9.83 mmol) in  $CH_2Cl_2$  (15 mL) was added dropwise titanium tetraisopropoxide (2.30 mL, 7.86 mmol) at  $-5^\circ C$ . After 20 min, TBHP (5.0 M in decane, 3.20 mL, 16.3 mmol) was added dropwise to the mixture at  $-20^\circ C$ . After stirring for 20 min at  $-20^\circ C$ , the resulting mixture was treated with a solution of **12** (1.40 g, 7.07 mmol) in  $CH_2Cl_2$  (7 mL) and then stirred at  $-20^\circ C$  for 15 h. The reaction was diluted with  $Et_2O$  (11 mL), warmed to room temperature, and

treated with Celite (10.0 g) and  $Na_2SO_4 \cdot 10H_2O$  (10.0 g). After stirring for 2 h at room temperature, the resulting mixture was filtered through a pad of Celite and concentrated in vacuo. The residue was purified by column chromatography (1:1 hexanes/EtOAc) to give a mixture of the corresponding epoxy alcohol and a small amount of (+)-DET. This mixture was employed in the next reaction without further purification.

To a solution of the mixture in  $CH_2Cl_2$  (70 mL), NCS (1.60 g, 11.9 mmol), triphenylphosphine (3.10 g, 11.9 mmol), and 2-methyloxirane (980  $\mu L$ , 14.0 mmol) were added. The reaction mixture was stirred for 10 min at room temperature and concentrated in vacuo. Flash chromatography (40:1 hexanes/EtOAc) afforded **7** (1.54 g, 94% for 2 steps) as a colorless oil.  $[\alpha]_D^{25} +4.0$  (c 0.1,  $CHCl_3$ ); IR (KBr) 2969, 2873, 1336, 1105  $cm^{-1}$ ;  $^1H$  NMR (270 MHz,  $CDCl_3$ )  $\delta$  3.92 (d, 1H,  $J=8.6$  Hz), 3.66 (d, 1H,  $J=8.6$  Hz), 3.58 (d, 2H,  $J=5.3$  Hz), 3.22 (dt, 1H,  $J=5.3, 2.0$  Hz), 2.99 (d, 1H,  $J=2.0$  Hz), 1.74 (m, 8H), 1.29 (s, 3H, 4-Me);  $^{13}C$  NMR (67.5 MHz,  $CDCl_3$ )  $\delta$  119.9, 77.9, 71.8, 61.7, 54.3, 44.0, 36.9, 36.7, 23.5, 23.2, 21.4; HRMS (FAB, *m*-NBA)  $M^+$  calcd for  $C_{11}H_{17}O_3Cl$ : 232.0866, found: 232.0868.

#### 4.3.6. (*R*)-1-[(*S*)-2-Methyl-1,4-dioxaspiro[4.4]nonan-2-yl]prop-2-yn-1-ol (**13**)

To a solution of **7** (1.53 g, 6.61 mmol) in THF (66 mL) was added *n*-BuLi (1.6 M in hexane, 20 mL, 33.0 mmol) at  $-78^\circ C$ . The reaction mixture was stirred for 2 h at  $-40^\circ C$ , quenched with a saturated aqueous  $NH_4Cl$  solution, and extracted with EtOAc. The combined organic extracts were dried over anhydrous  $Na_2SO_4$  and concentrated in vacuo. Flash chromatography (10:1 hexanes/EtOAc) afforded **13** (1.28 g, 99%) as a colorless oil.  $[\alpha]_D^{25} -12.0$  (c 0.1,  $CHCl_3$ ); IR (KBr) 3444, 3307, 2971, 2875, 1336, 1106, 1051  $cm^{-1}$ ;  $^1H$  NMR (270 MHz,  $CDCl_3$ )  $\delta$  4.32 (dd, 1H,  $J=4.0, 2.0$  Hz), 4.19 (d, 1H,  $J=8.7$  Hz), 3.68 (d, 1H,  $J=8.7$  Hz), 2.46 (d, 1H,  $J=2.0$  Hz), 2.33 (br d, 1H,  $J=4.0$  Hz), 1.77 (m, 8H), 1.40 (s, 3H);  $^{13}C$  NMR (67.5 MHz,  $CDCl_3$ )  $\delta$  120.1, 82.0, 81.7, 74.0, 70.8, 66.3, 37.0, 36.9, 23.6, 23.1, 20.8; HRMS (FAB, *m*-NBA)  $[M+H]^+$  calcd for  $C_{11}H_{17}O_3$ : 197.1178, found: 197.1183.

#### 4.3.7. (2*S*,3*R*)-3-(*tert*-Butyldimethylsilyloxy)-2-methylpent-4-yne-1,2-diol (**14**)

To a solution of **13** (1.29 g, 6.56 mmol) in  $CH_2Cl_2$  (65 mL) were added TBSOTf (3.00 mL, 13.1 mmol) and 2,6-lutidine (2.30 mL, 19.6 mmol) at  $0^\circ C$ . After 30 min at room temperature, the reaction was quenched with  $H_2O$  and extracted with  $CH_2Cl_2$ . The combined organic extracts were dried over anhydrous  $Na_2SO_4$  and concentrated in vacuo. This residue was employed in the next reaction without further purification.

The residue was dissolved in 70% aqueous AcOH solution (31 mL). The reaction mixture was stirred for 10 h at room temperature, quenched with a saturated aqueous  $NaHCO_3$  solution, and extracted with EtOAc. The combined organic extracts were dried over anhydrous  $Na_2SO_4$  and concentrated in vacuo. Flash chromatography (4:1 hexanes/EtOAc) afforded **14** (1.40 g, 87% for 2 steps) as a colorless oil.  $[\alpha]_D^{25} -45.2$  (c 1.0,  $CHCl_3$ ); IR (KBr) 3300, 2929, 2863, 1239, 1185, 1130, 1025  $cm^{-1}$ ;  $^1H$  NMR (270 MHz,  $CDCl_3$ )  $\delta$  4.35 (d, 1H,  $J=2.0$  Hz), 3.86 (d, 1H,  $J=11.2$  Hz), 3.43 (d, 1H,  $J=11.2$  Hz), 2.64 (br s, 2H), 2.47 (d, 1H,  $J=2.0$  Hz), 1.19 (s, 3H), 0.89 (s, 9H), 0.16 (s, 3H), 0.12 (s, 3H);  $^{13}C$  NMR (67.5 MHz,  $CDCl_3$ )  $\delta$  82.3, 74.8, 73.9, 69.2, 66.8, 25.6, 19.8, 18.0,  $-4.8$ ,  $-5.4$ ; HRMS (FAB, *m*-NBA)  $[M+H]^+$  calcd for  $C_{12}H_{25}O_3Si$ : 245.1573, found: 245.1569.

#### 4.3.8. (*S*)-5-[(*R*)-1-(*tert*-Butyldimethylsilyloxy)prop-2-ynyl]-3-hydroxy-5-methylfuran-2(5*H*)-one (**15**)

To a solution of **14** (161 mg, 657  $\mu mol$ ) in  $CH_2Cl_2$  (6.6 mL) were added TEMPO (20.5 mg, 131  $\mu mol$ ) and trichloroisocyanuric acid (153 mg, 657  $\mu mol$ ) at room temperature. The resulting solution was stirred for 30 min and diluted with a saturated aqueous



NaHCO<sub>3</sub> solution. The aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The crude aldehyde **5** was subjected to the next reaction without further purification.

To a solution of **6** (511 mg, 1.64 mmol) in CH<sub>3</sub>CN (4.0 mL) were added LiCl (63.8 mg, 1.51 mmol) and DBU (210  $\mu$ L, 1.51 mmol) at 0 °C. After stirring for 30 min, a solution of the crude aldehyde **5** in THF (1.3 mL) was slowly added dropwise over 60 min to the reaction mixture at 0 °C. After 5 min, the resulting solution was quenched with a saturated aqueous NaHCO<sub>3</sub> solution and extracted with EtOAc. The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. Flash chromatography (7:1 hexanes/EtOAc) afforded **15** (140 mg, 75% for 2 steps) as a colorless oil. [ $\alpha$ ]<sub>D</sub><sup>24</sup> –69.3 (c 0.5, CHCl<sub>3</sub>); IR (KBr) 3369, 3284, 2947, 2868, 1786, 1664, 1462, 1392, 1317, 1252, 1184, 1093, 989, 935, 849, 783, 677 cm<sup>–1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) enol  $\delta$  9.80 (s, 1H), 6.21 (s, 1H), 4.37 (d, 1H, *J* = 2.2 Hz), 2.50 (d, 1H, *J* = 2.2 Hz), 1.57 (s, 3H), 0.86 (s, 9H), 0.13 (s, 3H), 0.1 (s, 3H); ketone  $\delta$  4.39 (d, 1H, *J* = 2.2 Hz), 3.26 (d, 1H, *J* = 18.8 Hz), 2.55 (d, 1H, *J* = 2.2 Hz), 2.41 (d, 1H, *J* = 18.8 Hz), 1.69 (s, 3H), 0.83 (s, 9H), 0.14 (s, 3H), 0.1 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) as a keto–enol mixture,  $\delta$  191.5, 169.4, 160.2, 142.8, 128.3, 119.2, 86.3, 83.7, 81.2, 80.5, 76.1, 74.9, 68.5, 67.0, 41.1, 25.5, 25.4, 22.7, 20.7, 18.2, 18.0, –5.1, –5.4; HRMS (FAB, *m*-NBA) [M+H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>23</sub>O<sub>4</sub>Si: 283.1366, found: 283.1371.

#### 4.3.9. (S)-3-Hydroxy-5-[(R)-1-hydroxyprop-2-ynyl]-5-methylfuran-2(5H)-one (**16**)

A solution of **15** (17.1 mg, 0.06 mmol) in THF (1.2 mL) was treated with HF·pyridine (600  $\mu$ L) and stirred for 24 h at room temperature. The resulting mixture was filtered through a pad of silica gel and concentrated in vacuo. Flash chromatography (1:1 hexanes/EtOAc) afforded **16** (9.30 mg, 91%) as a colorless oil. [ $\alpha$ ]<sub>D</sub><sup>22</sup> –55.1 (c 0.5, CH<sub>3</sub>OH); IR (KBr) 3288, 2997, 2941, 2902, 2123, 1743, 1658, 1566, 1446, 1385, 1233, 1203, 1134, 1051, 978, 918, 868, 825, 781, 721, 642 cm<sup>–1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.08 (s, 1H), 4.31 (d, 1H, *J* = 2.3 Hz), 2.49 (d, 1H, *J* = 2.3 Hz), 1.48 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  169.6, 143.9, 119.1, 85.6, 80.5, 74.8, 66.0, 20.9; HRMS (FAB, *m*-NBA+Na) [M+Na]<sup>+</sup> calcd for C<sub>8</sub>H<sub>8</sub>O<sub>4</sub>Na: 191.0320, found: 191.0325.

#### 4.3.10. (S)-3-Hydroxy-5-[(R,E)-1-hydroxy-3-(tributylstannyl)allyl]-5-methylfuran-2(5H)-one (**3**) and (S)-3-hydroxy-5-[(S)-1-hydroxy-2-(tributylstannyl)allyl]-5-methylfuran-2(5H)-one (**17**)

To a stirred solution of **16** (36.4 mg, 217  $\mu$ mol) in THF (4.3 mL) were added tributyltin hydride (120  $\mu$ L, 0.43 mmol) and PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (4.4 mg, 10.8  $\mu$ mol). The resulting mixture was stirred for 30 min at room temperature and then concentrated in vacuo. The residue was purified by column chromatography (7:1 hexanes/EtOAc) to give **3** (38.9 mg, 39%) and **17** (30.0 mg, 30%) as white solids.

Compound **3**: see Section 4.3.15.

Compound **17**: mp 69–72 °C; [ $\alpha$ ]<sub>D</sub><sup>22</sup> –10.1 (c 0.5, CHCl<sub>3</sub>); IR (KBr) 3469, 3194, 3086, 2951, 2920, 2856, 1739, 1687, 1645, 1415, 1336, 1273, 1219, 1124, 1068, 1034, 985, 937, 785, 690 cm<sup>–1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) enol  $\delta$  9.75 (s, 1H), 6.38 (dd, 1H, *J* = 19.2, 1.3 Hz), 5.97 (dd, 1H, *J* = 19.2, 5.5 Hz), 4.20 (br d, 1H, *J* = 4.9 Hz), 1.55–1.42 (m, 6H), 1.45 (s, 3H), 1.39–1.25 (m, 6H), 0.94–0.83 (m, 6H), 0.89 (t, 9H, *J* = 7.2 Hz); ketone  $\delta$  6.50 (dd, 1H, *J* = 19.2, 1.5 Hz), 6.14 (s, 1H), 5.94 (dd, 1H, *J* = 19.2, 5.3 Hz), 4.31 (br d, 1H, *J* = 4.7 Hz), 3.00 (d, 1H, *J* = 18.8 Hz), 2.29 (d, 1H, *J* = 18.8 Hz), 1.57 (s, 3H), 1.55–1.42 (m, 6H), 1.39–1.25 (m, 6H), 0.94–0.83 (m, 6H), 0.89 (t, 9H, *J* = 7.2 Hz); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) as a keto–enol mixture,  $\delta$  192.2, 169.4, 160.6, 143.6, 142.7, 142.5, 135.5, 133.5, 120.3, 86.8, 84.3, 78.5, 78.3, 40.0, 29.0, 27.2, 23.5, 21.1, 13.7, 9.6; HRMS (FAB, *m*-NBA+Na) [M+Na]<sup>+</sup> calcd for C<sub>20</sub>H<sub>36</sub>O<sub>4</sub>SnNa: 483.1533, found: 483.1534.

#### 4.3.11. (S)-5-[(R,E)-1-(tert-Butyldimethylsilyloxy)-3-(tributylstannyl)allyl]-3-hydroxy-5-methylfuran-2(5H)-one (**18**) and (S)-5-[(S)-1-(tert-butyldimethylsilyloxy)-2-(tributylstannyl)allyl]-3-hydroxy-5-methylfuran-2(5H)-one (**19**)

To a stirred solution of **15** (18.0 mg, 63.8  $\mu$ mol) in THF (640  $\mu$ L) were added tributyltin hydride (50  $\mu$ L, 19.1  $\mu$ mol) and PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (1.3 mg, 3.19  $\mu$ mol). The resulting mixture was stirred for 30 min at room temperature and then concentrated in vacuo. The residue was purified by column chromatography (7:1 hexanes/EtOAc) to give **18** (19.1 mg, 52%) and **19** (8.4 mg, 23%) as colorless oils.

Compound **18**: [ $\alpha$ ]<sub>D</sub><sup>24</sup> –32.5 (c 0.5, CHCl<sub>3</sub>); IR (KBr) 2952, 2927, 2858, 1786, 1462, 1385, 1306, 1254, 1184, 1086, 1001, 849, 781, 681 cm<sup>–1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) enol  $\delta$  9.63 (s, 1H), 6.32 (dd, 1H, *J* = 19.1, 1.3 Hz), 5.91 (dd, 1H, *J* = 19.1, 5.9 Hz), 4.09 (dd, 1H, *J* = 5.9, 1.3 Hz), 1.57–1.42 (m, 6H), 1.39 (s, 3H), 1.36–1.24 (m, 6H), 0.93–0.79 (m, 6H), 0.88 (t, 9H, *J* = 7.3 Hz), 0.81 (s, 9H), –0.02 (s, 3H); ketone  $\delta$  6.43 (dd, 1H, *J* = 19.1, 1.3 Hz), 6.08 (s, 1H), 5.85 (dd, 1H, *J* = 19.1, 5.9 Hz), 4.18 (dd, 1H, *J* = 5.9, 1.3 Hz), 2.99 (d, 1H, *J* = 18.6 Hz), 2.23 (d, 1H, *J* = 18.6 Hz), 1.57–1.42 (m, 6H), 1.52 (s, 3H), 1.36–1.24 (m, 6H), 0.93–0.79 (m, 6H), 0.88 (t, 9H, *J* = 7.3 Hz), 0.81 (s, 9H), –0.02 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) as a keto–enol mixture,  $\delta$  192.2, 169.7, 160.6, 145.5, 144.1, 142.3, 136.0, 133.3, 120.3, 87.1, 84.3, 80.4, 79.5, 40.3, 29.1, 27.2, 25.7, 23.5, 20.8, 18.0, 13.7, 9.6, –4.5, –4.6, –5.2, –5.4; HRMS (FAB, *m*-NBA+Na) [M+Na]<sup>+</sup> calcd for C<sub>26</sub>H<sub>50</sub>O<sub>4</sub>SiSnNa: 597.2398, found: 597.2404.

Compound **19**: [ $\alpha$ ]<sub>D</sub><sup>24</sup> –18.8 (c 0.5, CHCl<sub>3</sub>); IR (KBr) 3477, 3346, 2957, 2927, 2858, 1753, 1687, 1658, 1462, 1384, 1255, 1219, 1153, 1070, 937, 866, 839, 781, 675 cm<sup>–1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) enol  $\delta$  6.19 (s, 1H), 6.08 (m, 1H), 5.43 (dd, 1H, *J* = 2.5, 1.0 Hz), 4.20 (s, 1H), 1.51–1.41 (m, 6H), 1.38–1.25 (m, 6H), 1.31 (s, 3H), 1.04–0.81 (m, 24H), 0.03 (s, 6H), –0.04 (s, 6H); ketone  $\delta$  6.16 (m, 1H), 5.50 (dd, 1H, *J* = 2.5, 1.0 Hz), 4.41 (s, 1H), 3.14 (d, 1H, *J* = 18.8 Hz), 2.19 (d, 1H, *J* = 18.8 Hz), 1.51–1.41 (m, 6H), 1.49 (s, 3H), 1.38–1.25 (m, 6H), 1.04–0.81 (m, 24H), 0.03 (s, 6H), –0.03 (s, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) as a keto–enol mixture,  $\delta$  192.3, 169.4, 160.4, 153.1, 152.2, 141.8, 131.1, 128.8, 122.5, 87.1, 84.9, 81.9, 40.0, 29.0, 28.9, 27.4, 27.3, 25.8, 25.7, 24.5, 20.0, 18.1, 18.0, 13.6, 13.5, 12.4, 12.3, –4.3, –4.0, –5.2, –5.5; HRMS (FAB, *m*-NBA+Na) [M+Na]<sup>+</sup> calcd for C<sub>26</sub>H<sub>50</sub>O<sub>4</sub>SiSnNa: 597.2398, found: 597.2404.

#### 4.3.12. (S)-3-(tert-Butyldimethylsilyloxy)-5-[(R)-1-(tert-butyl-dimethylsilyloxy)prop-2-ynyl]-5-methylfuran-2(5H)-one (**20**)

To a solution of **14** (63.0 mg, 257  $\mu$ mol) in CH<sub>2</sub>Cl<sub>2</sub> (2.6 mL) were added TEMPO (8.03 mg, 51.4  $\mu$ mol) and trichloroisocyanuric acid (59.7 mg, 257  $\mu$ mol) at room temperature. The resulting solution was stirred for 30 min and diluted with a saturated aqueous NaHCO<sub>3</sub> solution. The aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The crude aldehyde **5** was subjected to the next reaction without further purification.

To a solution of **6** (201 mg, 646  $\mu$ mol) in THF (1.3 mL) was added LHMSD (1.0 M solution in THF, 590  $\mu$ L, 590  $\mu$ mol) at 0 °C. After stirring for 30 min, a solution of the crude aldehyde **5** in THF (1.3 mL) was slowly added dropwise over 30 min to the reaction mixture at 0 °C. After 5 min, the resulting solution was quenched with a saturated aqueous NH<sub>4</sub>Cl solution and extracted with EtOAc. The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. Flash chromatography (50:1 hexanes/EtOAc) afforded **20** (76.4 mg, 75% for 2 steps) as a colorless oil. [ $\alpha$ ]<sub>D</sub><sup>23</sup> –65.2 (c 3.1, CHCl<sub>3</sub>); IR (KBr) 2933, 2858, 1760, 1656, 1257, 1130, 1079, 842 cm<sup>–1</sup>; <sup>1</sup>H NMR (270 MHz, CDCl<sub>3</sub>)  $\delta$  6.20 (s, 1H), 4.34 (d, 1H, *J* = 2.0 Hz), 2.48 (d, 1H, *J* = 2.0 Hz), 1.53 (s, 3H), 0.96 (s, 9H), 0.87 (s, 9H), 0.25 (s, 6H), 0.13 (s, 3H), 0.09 (s, 3H); <sup>13</sup>C NMR (67.5 MHz, CDCl<sub>3</sub>)  $\delta$  168.5, 143.4, 124.6, 84.3, 81.5, 74.7, 67.2, 25.5, 25.4, 20.9, 18.2, 18.0, –4.8, –4.9, –5.0, –5.3; HRMS (FAB, *m*-NBA) [M+H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>37</sub>O<sub>4</sub>Si<sub>2</sub>: 397.2230, found: 397.2227.

#### 4.3.13. (S)-5-[(R)-3-Bromo-1-(tert-butyldimethylsilyloxy)prop-2-ynyl]-3-(tert-butyldimethylsilyloxy)-5-methylfuran-2(5H)-one (**21**)

To a stirred solution of **20** (227 mg, 573  $\mu$ mol) in acetone (5.7 mL) were added NBS (111 mg, 631  $\mu$ mol) and silver(I) nitrate (11.0 mg, 57.3  $\mu$ mol). The resulting solution was stirred for 1 h at room temperature, filtered through a pad of silica gel, and concentrated in vacuo. The residue was purified by column chromatography (50:1 hexanes/EtOAc) to give **21** (272 mg, 100%) as a colorless oil.  $[\alpha]_D^{23}$  –52.8 (c 2.7, CHCl<sub>3</sub>); IR (KBr) 2931, 2859, 1753, 1652, 1259, 1078 cm<sup>-1</sup>; <sup>1</sup>H NMR (270 MHz, CDCl<sub>3</sub>)  $\delta$  6.16 (s, 1H), 4.34 (s, 1H), 1.51 (s, 3H), 0.96 (s, 9H), 0.86 (s, 9H), 0.24 (s, 6H), 0.11 (s, 3H), 0.07 (s, 3H); <sup>13</sup>C NMR (67.5 MHz, CDCl<sub>3</sub>)  $\delta$  168.4, 143.4, 124.8, 84.2, 77.8, 68.4, 46.9, 25.5, 25.4, 20.9, 18.2, 18.0, –4.8, –4.9, –5.0, –5.3; HRMS (FAB, *m*-NBA+Na) [M+Na]<sup>+</sup> calcd for C<sub>20</sub>H<sub>35</sub>O<sub>4</sub>Br-Si<sub>2</sub>Na: 497.1154, found: 497.1173.

#### 4.3.14. (S)-5-[(R)-3-Bromo-1-hydroxyprop-2-ynyl]-3-hydroxy-5-methylfuran-2(5H)-one (**22**)

To a stirred solution of **21** (273 mg, 576  $\mu$ mol) in THF (6 mL) was added HF-pyridine (2 mL). The resulting solution was stirred for 24 h at room temperature, filtered through a pad of silica gel, and concentrated in vacuo. The residue was purified by column chromatography (2:1 hexanes/EtOAc) to give **22** (142 mg, 100%) as a colorless oil.  $[\alpha]_D^{23}$  –30.7 (c 1.0, MeOH); IR (KBr) 3322, 3153, 2991, 2877, 1743, 1662, 1201, 1132, 1018 cm<sup>-1</sup>; <sup>1</sup>H NMR (270 MHz, CDCl<sub>3</sub>) enol  $\delta$  6.21 (s, 1H), 4.46 (s, 1H), 1.07 (s, 3H); ketone  $\delta$  4.53 (s, 1H), 3.25 (d, 1H, *J*=19.1 Hz), 2.49 (d, 1H, *J*=19.1 Hz), 1.59 (s, 3H); HRMS (FAB, *m*-NBA+Na) [M+Na]<sup>+</sup> calcd for C<sub>8</sub>H<sub>7</sub>O<sub>4</sub>BrNa: 268.9425, found: 268.9417.

#### 4.3.15. (S)-3-Hydroxy-5-[(R,E)-1-hydroxy-3-(tributylstannyl)allyl]-5-methylfuran-2(5H)-one (**3**)

To a stirred solution of **22** (48.0 mg, 195  $\mu$ mol) in THF (2 mL) was added tributyltin hydride (500  $\mu$ L, 1.85 mmol). The resulting mixture was stirred for 30 min at room temperature and then concentrated in vacuo. The residue was purified by column chromatography (7:1 hexanes/EtOAc) to give **3** (63.8 mg, 71%) as a white solid. Mp 78–80 °C;  $[\alpha]_D^{22}$  –32.9 (c 0.5, CHCl<sub>3</sub>); IR (KBr) 3539, 3454, 3369, 3140, 3074, 2920, 2858, 1732, 1653, 1458, 1377, 1294, 1201, 1144, 1061, 993, 870, 787, 673 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) enol  $\delta$  9.75 (s, 1H), 6.38 (dd, 1H, *J*=19.2, 1.3 Hz), 5.97 (dd, 1H, *J*=19.2, 5.5 Hz), 4.20 (br d, 1H, *J*=4.9 Hz), 1.55–1.42 (m, 6H), 1.45 (s, 3H), 1.39–1.25 (m, 6H), 0.94–0.83 (m, 6H), 0.89 (t, 9H, *J*=7.2 Hz); ketone  $\delta$  6.50 (dd, 1H, *J*=19.2, 1.5 Hz), 6.14 (s, 1H), 5.94 (dd, 1H, *J*=19.2, 5.3 Hz), 4.31 (br d, 1H, *J*=4.7 Hz), 3.00 (d, 1H, *J*=18.8 Hz), 2.29 (d, 1H, *J*=18.8 Hz), 1.57 (s, 3H), 1.55–1.42 (m, 6H), 1.39–1.25 (m, 6H), 0.94–0.83 (m, 6H), 0.89 (t, 9H, *J*=7.2 Hz); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) as a keto-enol mixture,  $\delta$  192.2, 169.4, 160.6, 143.6, 142.7, 142.5, 135.5, 133.5, 120.3, 86.8, 84.3, 78.5, 78.3, 40.0, 29.0, 27.2, 23.5, 21.1, 13.7, 9.6; HRMS (FAB, *m*-NBA+Na) [M+Na]<sup>+</sup> calcd for C<sub>20</sub>H<sub>36</sub>O<sub>4</sub>SnNa: 483.1533, found: 483.1528.

#### 4.3.16. Nafuredin- $\gamma$ (**2**)

To a stirred solution of **3** (16.4 mg, 35.6  $\mu$ mol) and **4** (14.7 mg, 46.3  $\mu$ mol) in *N*-methyl pyrrolidinone (NMP) (500  $\mu$ L) was added bisacetoneitriledichloropalladium (1.00 mg, 3.85  $\mu$ mol). The resulting mixture was stirred for 30 min at 50 °C, quenched with a saturated aqueous NH<sub>4</sub>Cl solution, and extracted with EtOAc. The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. Flash chromatography (4:1 hexanes/EtOAc) afforded **2** (9.24 mg, 72%) as a colorless oil.  $[\alpha]_D^{25}$  +4.0 (c 0.1, CHCl<sub>3</sub>); IR (KBr) 3374, 2960, 2925, 2858, 1754, 1737, 1660, 1261, 1101 cm<sup>-1</sup>; <sup>1</sup>H NMR (270 MHz, CDCl<sub>3</sub>) enol  $\delta$  6.30 (dd, 1H, *J*=15.5, 10.2 Hz), 6.18 (dd, 1H, *J*=14.8, 10.9 Hz), 6.15 (s, 1H), 6.00 (dd, 1H, *J*=15.5, 10.2 Hz), 5.76 (d, 1H, *J*=10.9 Hz), 5.70 (dd, 1H, *J*=15.5, 7.3 Hz), 5.50 (dd, 1H, *J*=15.5, 7.3 Hz), 5.46 (dd, 1H, *J*=14.8, 7.6 Hz),

4.25 (d, 1H, *J*=7.3 Hz), 2.43–2.36 (m, 1H), 2.12–1.91 (m, 3H), 1.70 (s, 3H), 1.46 (s, 3H), 1.32 (m, 2H), 0.99 (d, 3H, *J*=6.6 Hz), 0.97 (s, 3H, *J*=6.7 Hz), 0.86 (t, 3H, *J*=7.6 Hz); ketone  $\delta$  6.30 (dd, 1H, *J*=15.5, 10.2 Hz), 6.18 (dd, 1H, *J*=14.8, 10.9 Hz), 6.00 (dd, 1H, *J*=15.5, 10.2 Hz), 5.76 (d, 1H, *J*=10.9 Hz), 5.70 (dd, 1H, *J*=15.5, 7.3 Hz), 5.50 (dd, 1H, *J*=15.5, 7.3 Hz), 5.46 (dd, 1H, *J*=14.8, 7.6 Hz), 4.21 (m, 1H), 3.03 (d, 1H, *J*=18.8 Hz), 2.43–2.36 (m, 1H), 2.32 (d, 1H, *J*=18.8 Hz), 2.12–1.91 (m, 3H), 1.70 (s, 3H), 1.54 (s, 3H), 1.32 (m, 2H), 0.99 (d, 3H, *J*=6.6 Hz), 0.97 (s, 3H, *J*=6.7 Hz), 0.86 (t, 3H, *J*=7.6 Hz); HRMS (FAB, *m*-NBA) [M+H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>33</sub>O<sub>4</sub>: 361.2379, found: 361.2372.

### 4.4. Synthesis of nafuredin analogues **23**, **24**, and **25**

#### 4.4.1. Synthesis of **26**, **27**, and **28**

These compounds were prepared according to the syntheses of **8**, **10**, and **12**.

#### 4.4.2. (R)-2-[(2R,3R)-3-(Chloromethyl)oxiran-2-yl]-2-methyl-1,4-dioxaspiro[4.4]nonane (**29**)

According to the conversion of **12** into **7**, **28** (537 mg, 2.71 mmol) gave **29** (541 mg, 86% for 2 steps) as a colorless oil. <sup>1</sup>H NMR (270 MHz, CDCl<sub>3</sub>)  $\delta$  3.90 (d, 1H, *J*=8.9 Hz), 3.63 (dd, 1H, *J*=11.5, 6.4 Hz), 3.61 (d, 1H, *J*=8.9 Hz), 3.52 (dd, 1H, *J*=11.5, 6.4 Hz), 3.28 (dt, 1H, *J*=6.4, 2.0 Hz), 2.90 (d, 1H, *J*=2.0 Hz), 1.78–1.56 (m, 8H), 1.33 (s, 3H).

#### 4.4.3. (R)-1-[(R)-2-Methyl-1,4-dioxaspiro[4.4]nonan-2-yl]prop-2-yn-1-ol (**30**)

According to the conversion of **7** into **13**, **29** (541 mg, 2.33 mmol) afforded **30** (453 mg, 99%) as a colorless oil. <sup>1</sup>H NMR (270 MHz, CDCl<sub>3</sub>)  $\delta$  4.31 (dd, 1H, *J*=4.6, 2.2 Hz), 4.03 (d, 1H, *J*=8.9 Hz), 3.68 (d, 1H, *J*=8.9 Hz), 2.46 (d, 1H, *J*=2.2 Hz), 2.39 (d, 1H, *J*=4.6 Hz), 1.84–1.59 (m, 8H), 1.42 (s, 3H).

#### 4.4.4. (2R,3R)-3-(tert-Butyldimethylsilyloxy)-2-methylpent-4-yne-1,2-diol (**31**)

According to the conversion of **13** into **14**, **30** (454 mg, 2.32 mmol) furnished **31** (435 mg, 77% for 2 steps) as a colorless oil. <sup>1</sup>H NMR (270 MHz, CDCl<sub>3</sub>)  $\delta$  4.42 (d, 1H, *J*=2.2 Hz), 3.68 (dd, 1H, *J*=11.4, 6.3 Hz), 3.56 (dd, 1H, *J*=11.4, 5.3 Hz), 2.61 (s, 1H), 2.48 (d, 1H, *J*=2.2 Hz), 2.07 (br s, 1H), 1.21 (s, 3H), 0.92 (s, 9H), 0.20 (s, 3H), 0.16 (s, 3H).

#### 4.4.5. (R)-3-Hydroxy-5-[(R)-1-hydroxyprop-2-ynyl]-5-methylfuran-2(5H)-one (**32**)

To a solution of **31** (436 mg, 1.79 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (17.8 mL) were added TEMPO (5.60 mg, 35.7  $\mu$ mol) and trichloroisocyanuric acid (415 mg, 1.79 mmol) at 0 °C. After 35 min at 0 °C, the reaction mixture was filtered through a pad of Celite and concentrated in vacuo. This crude aldehyde was employed in the next reaction without further purification.

To a solution of **6** (1.40 g, 4.46 mmol) in THF (17.8 mL) was added LHMDS (1.0 M solution in THF, 4.12 mL, 4.12 mmol) at 0 °C. After stirring for 30 min, a solution of the crude aldehyde in THF (17.8 mL) was slowly added dropwise over 30 min to the reaction mixture at 0 °C. After 10 min, the reaction mixture was quenched with a saturated aqueous NH<sub>4</sub>Cl solution and extracted with EtOAc. The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. This crude lactone was employed in the next reaction without further purification.

A solution of the crude lactone in THF (8.8 mL) was treated with HF-pyridine (200  $\mu$ L) and stirred for 24 h at room temperature. The resulting mixture was filtered through a pad of silica gel and concentrated in vacuo. Flash chromatography (1:1 hexanes/EtOAc) afforded **32** (155 mg, 52% for 3 steps) as a colorless oil. <sup>1</sup>H NMR (270 MHz, CDCl<sub>3</sub>) enol  $\delta$  6.25 (s, 1H), 4.36 (s, 1H), 2.56 (d, 1H,



$J=2.0$  Hz), 1.62 (s, 3H); ketone  $\delta$  4.42 (m, 1H), 3.31 (d, 1H,  $J=19.4$  Hz), 2.63 (d, 1H,  $J=2.0$  Hz), 2.55 (d, 1H,  $J=19.4$  Hz), 1.72 (s, 3H).

#### 4.4.6. (*R*)-3-(*tert*-Butyldiphenylsilyloxy)-5-[(*R,E*)-1-hydroxy-3-(tributylstannyl)allyl]-5-methylfuran-2(5H)-one (**33**)

To a solution of **32** (155 mg, 0.92 mmol) in THF (9.2 mL) were added  $\text{Et}_3\text{N}$  (193  $\mu\text{L}$ , 1.39 mmol) and TBDPSCl (288  $\mu\text{L}$ , 1.11 mmol) at room temperature. The reaction mixture was stirred for 40 min, quenched with a saturated aqueous  $\text{NH}_4\text{Cl}$  solution, and extracted with EtOAc. The combined organic extracts were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated in vacuo. Flash chromatography (5:1 hexanes/EtOAc) afforded the corresponding TBDPS enol ether (**33**) (210 mg, 56%) as a colorless oil.  $^1\text{H}$  NMR (270 MHz,  $\text{CDCl}_3$ )  $\delta$  7.71–7.40 (m, 10H), 5.62 (s, 1H), 4.04 (d, 1H,  $J=2.3$  Hz), 2.35 (d, 1H,  $J=2.3$  Hz), 1.33 (s, 3H), 1.13 (s, 9H).

The TBDPS enol ether (**33**) (210 mg, 0.52 mmol) was dissolved in THF (4.9 mL) and treated with  $\text{PdCl}_2(\text{PPh}_3)_2$  (10.1 mg, 24.4  $\mu\text{mol}$ ) and  $\text{Bu}_3\text{SnH}$  (262  $\mu\text{L}$ , 0.974 mmol) at  $0^\circ\text{C}$ . After 1 h, the reaction mixture was quenched with  $\text{H}_2\text{O}$  and extracted with EtOAc. The combined organic extracts were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated in vacuo. Flash chromatography (50:1 hexanes/EtOAc) afforded **33** (303 mg, 47%) as a white solid. Mp  $49\text{--}50^\circ\text{C}$ ;  $[\alpha]_D^{24} +31.4$  (c 0.5,  $\text{CHCl}_3$ ); IR (KBr) 3427, 2924, 2858, 1749, 1647, 1462, 1433, 1238, 1200, 1109, 1068, 833, 754, 702  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.73–7.67 (m, 4H), 7.50–7.38 (m, 6H), 5.96 (dd, 1H,  $J=19.0$ , 1.0 Hz), 5.60 (dd, 1H,  $J=19.0$ , 6.0 Hz), 5.50 (s, 1H), 3.67 (m, 1H), 2.02 (d, 1H,  $J=3.0$  Hz), 1.46–1.36 (m, 6H), 1.29–1.19 (m, 6H), 1.16 (s, 3H), 1.12 (s, 9H), 0.88–0.80 (m, 15H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  168.3, 143.4, 142.3, 135.5, 135.4, 134.1, 130.5, 130.4, 128.0, 127.6, 85.3, 80.1, 29.0, 27.1, 26.2, 19.4, 18.7, 13.6, 9.4; HRMS (FAB, *m*-NBA+Na)  $[\text{M}+\text{Na}]^+$  calcd for  $\text{C}_{36}\text{H}_{54}\text{O}_4\text{SiSnNa}$ : 721.2711, found: 721.2700.

#### 4.4.7. C4-epimer (**23**)

To a solution of **33** (65.2 mg, 93.3  $\mu\text{mol}$ ) in NMP (2 mL) were added **4** (39.0 mg, 0.123 mmol) and  $\text{PdCl}_2(\text{MeCN})_2$  (2.40 mg, 9.43  $\mu\text{mol}$ ). After stirring for 1.5 h at  $50^\circ\text{C}$ , the reaction mixture was quenched with  $\text{H}_2\text{O}$  and extracted with EtOAc. The combined organic extracts were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated in vacuo. Flash chromatography (20:1 hexanes/EtOAc) afforded the corresponding coupling product (17.9 mg, 32%) as a colorless oil.  $^1\text{H}$  NMR (270 MHz,  $\text{CDCl}_3$ )  $\delta$  7.71–7.41 (m, 10H), 6.25 (m, 1H), 6.18 (m, 1H), 6.17 (s, 1H), 6.01 (m, 1H), 5.74 (d, 1H,  $J=10.7$  Hz), 5.59 (m, 1H), 5.58 (m, 1H), 5.39 (m, 1H), 4.10 (m, 1H), 2.40 (m, 1H), 2.31 (m, 1H), 1.93 (m, 2H), 1.67 (s, 3H), 1.32 (s, 3H), 1.25 (m, 2H), 0.93 (d, 3H,  $J=6.6$  Hz), 0.90 (d, 3H,  $J=6.8$  Hz), 0.80 (t, 3H,  $J=7.4$  Hz), 0.79 (s, 9H).

The coupling product (17.9 mg, 29.9  $\mu\text{mol}$ ) was dissolved in THF (5 mL) and treated with HF·pyridine (200  $\mu\text{L}$ ). After stirring for 24 h at room temperature, the resulting mixture was filtered through a pad of silica gel and concentrated in vacuo. Flash chromatography (4:1 hexanes/EtOAc) afforded the C4-epimer (**23**) (9.20 mg, 85%) as a colorless oil.  $[\alpha]_D^{27} +114.3$  (c 0.52,  $\text{CHCl}_3$ ); IR (KBr) 3446, 2961, 2925, 2860, 2360, 2300, 1749, 1717, 1698, 1683, 1653, 1636, 1558, 1540, 1521, 1507, 1488, 1456, 1418, 1376, 1203, 1130, 1078, 991, 970  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) enol  $\delta$  6.27 (dd, 1H,  $J=15.5$ , 10.4 Hz), 6.17 (dd, 1H,  $J=15.2$ , 11.1 Hz), 6.15 (s, 1H), 6.00 (dd, 1H,  $J=15.2$ , 10.4 Hz), 5.76 (d, 1H,  $J=11.1$  Hz), 5.69 (dd, 1H,  $J=15.2$ , 7.3 Hz), 5.50–5.43 (m, 2H), 4.12 (d, 1H,  $J=8.0$  Hz), 2.46–2.37 (m, 1H), 2.12–1.94 (m, 3H), 1.70 (s, 3H), 1.47 (s, 3H), 1.32 (m, 2H), 0.99 (d, 3H,  $J=6.6$  Hz), 0.97 (d, 3H,  $J=6.8$  Hz), 0.86 (t, 3H,  $J=7.4$  Hz); ketone  $\delta$  6.27 (dd, 1H,  $J=15.5$ , 10.4 Hz), 6.17 (dd, 1H,  $J=15.2$ , 11.1 Hz), 6.00 (dd, 1H,  $J=15.2$ , 10.4 Hz), 5.76 (d, 1H,  $J=11.1$  Hz), 5.69 (dd, 1H,  $J=15.2$ , 7.3 Hz), 5.50–5.43 (m, 2H), 4.06 (d, 1H,  $J=8.0$  Hz), 3.08 (d, 1H,  $J=18.6$  Hz), 2.51 (d, 1H,  $J=18.6$  Hz), 2.46–2.37 (m, 1H), 2.12–1.94 (m, 3H), 1.70 (s, 3H), 1.53 (s, 3H), 1.32 (m, 2H), 0.99 (d, 3H,  $J=6.6$  Hz), 0.97 (d, 3H,  $J=6.8$  Hz), 0.86 (t, 3H,  $J=7.4$  Hz);  $^{13}\text{C}$  NMR (150 MHz,  $\text{CDCl}_3$ ) as a keto–enol mixture,  $\delta$  191.9, 160.6, 144.0, 143.0, 138.8, 138.7, 137.5, 135.4, 134.0, 133.9,

126.9, 126.8, 125.9, 125.2, 124.7, 120.7, 87.3, 83.2, 78.2, 77.4, 47.4, 47.3, 43.8, 38.6, 34.8, 29.8, 29.7, 23.4, 20.2, 19.8, 19.6, 16.5, 11.8; HRMS (FAB, *m*-NBA)  $[\text{M}+\text{Na}]^+$  calcd for  $\text{C}_{22}\text{H}_{32}\text{O}_4\text{Na}$ : 383.2198, found: 383.2192.

#### 4.4.8. (*S*)-2-[(2*S*,3*S*)-3-(Chloromethyl)oxiran-2-yl]-2-methyl-1,4-dioxaspiro[4.4]nonane (**34**)

According to the conversion of **12** into **7**, **12** (2.17 g, 10.9 mmol) was subjected to Sharpless epoxidation using (–)-DET followed by chlorination to afford **34** (2.34 g, 92% for 2 steps) as a yellow oil.  $^1\text{H}$  NMR (270 MHz,  $\text{CDCl}_3$ )  $\delta$  3.91 (d, 1H,  $J=8.9$  Hz), 3.74 (dd, 1H,  $J=11.5$ , 5.3 Hz), 3.62 (d, 1H,  $J=8.9$  Hz), 3.51 (dd, 1H,  $J=11.5$ , 5.3 Hz), 3.28 (ddd, 1H,  $J=10.7$ , 5.3, 1.7 Hz), 2.89 (d, 1H,  $J=1.7$  Hz), 1.86–1.56 (m, 8H), 1.33 (s, 3H).

#### 4.4.9. (*S*)-1-[(*S*)-2-Methyl-1,4-dioxaspiro[4.4]nonan-2-yl]prop-2-yn-1-ol (**35**)

According to the conversion of **29** into **30**, **34** (2.34 g, 10.1 mmol) gave **35** (1.92 g, 97%) as a yellow oil.  $^1\text{H}$  NMR (270 MHz,  $\text{CDCl}_3$ )  $\delta$  4.31 (dd, 1H,  $J=4.6$ , 2.0 Hz), 4.03 (d, 1H,  $J=8.9$  Hz), 3.68 (d, 1H,  $J=8.9$  Hz), 2.45 (d, 1H,  $J=2.0$  Hz), 2.39 (d, 1H,  $J=4.6$  Hz), 1.84–1.67 (m, 8H), 1.42 (s, 3H).

#### 4.4.10. (2*S*,3*S*)-3-(*tert*-Butyldimethylsilyloxy)-2-methylpent-4-yne-1,2-diol (**36**)

According to the conversion of **30** into **31**, **35** (1.92 g, 9.79 mmol) gave **36** (1.98 g, 83% for 2 steps) as a yellow oil.  $^1\text{H}$  NMR (270 MHz,  $\text{CDCl}_3$ )  $\delta$  4.42 (d, 1H,  $J=2.3$  Hz), 3.68 (dd, 1H,  $J=11.3$ , 6.9 Hz), 3.55 (dd, 1H,  $J=11.3$ , 5.9 Hz), 2.60 (s, 1H), 2.48 (d, 1H,  $J=2.3$  Hz), 2.11–2.04 (m, 1H), 1.24 (s, 3H), 0.92 (s, 9H), 0.20 (s, 3H), 0.16 (s, 3H).

#### 4.4.11. (*S*)-3-Hydroxy-5-[(*S*)-1-hydroxyprop-2-ynyl]-5-methylfuran-2(5H)-one (**37**)

According to the conversion of **31** into **32**, **36** (1.03 g, 4.22 mmol) gave **37** (347 mg, 49% for 3 steps) as a yellow oil.  $^1\text{H}$  NMR (270 MHz,  $\text{CDCl}_3$ )  $\delta$  6.25 (s, 1H, enol), 4.42 (br s, 1H, ketone), 4.36 (br s, 1H, enol), 3.13 (d, 1H,  $J=19.3$  Hz, ketone), 2.56 (d, 1H,  $J=2.0$  Hz), 2.54 (d, 1H,  $J=19.3$  Hz, ketone), 1.71 (s, 3H).

#### 4.4.12. (*S*)-3-(*tert*-Butyldiphenylsilyloxy)-5-[(*S,E*)-1-hydroxy-3-(tributylstannyl)allyl]-5-methylfuran-2(5H)-one (**38**)

According to the conversion of **32** into **33**, **37** (199 mg, 1.18 mmol) gave **38** (389 mg, 47% for 2 steps) as a white solid. Mp  $61\text{--}62^\circ\text{C}$ ;  $[\alpha]_D^{23} -37.5$  (c 0.5,  $\text{CHCl}_3$ ); IR (KBr) 3425, 2954, 2924, 2858, 1749, 1645, 1462, 1431, 1240, 1198, 1109, 1068, 833, 754, 702  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.73–7.67 (m, 4H), 7.50–7.38 (m, 6H), 5.96 (dd, 1H,  $J=19.0$ , 1.0 Hz), 5.60 (dd, 1H,  $J=19.0$ , 6.0 Hz), 5.50 (s, 1H), 3.67 (m, 1H), 2.02 (d, 1H,  $J=3.0$  Hz), 1.46–1.36 (m, 6H), 1.29–1.19 (m, 6H), 1.16 (s, 3H), 1.12 (s, 9H), 0.88–0.80 (m, 15H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  168.3, 143.4, 142.3, 135.5, 135.4, 134.1, 130.5, 130.4, 128.0, 127.6, 85.3, 80.1, 29.0, 27.1, 26.2, 19.4, 18.7, 13.6, 9.4; HRMS (FAB, *m*-NBA+Na)  $[\text{M}+\text{Na}]^+$  calcd for  $\text{C}_{36}\text{H}_{54}\text{O}_4\text{SiSnNa}$ : 721.2711, found: 721.2719.

#### 4.4.13. C5-epimer (**24**)

To a solution of **38** (35.3 mg, 0.051 mmol) in NMP (1.01 mL) were added **4** (20.9 mg, 0.066 mmol) and  $\text{PdCl}_2(\text{MeCN})_2$  (1.31 mg, 5.00  $\mu\text{mol}$ ). After stirring for 4 h at  $50^\circ\text{C}$ , the reaction mixture was quenched with  $\text{H}_2\text{O}$  and extracted with EtOAc. The combined organic extracts were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated in vacuo. Flash chromatography (20:1 hexanes/EtOAc) afforded the corresponding coupling product (8.50 mg, 28%) as a colorless oil.  $^1\text{H}$  NMR (270 MHz,  $\text{CDCl}_3$ )  $\delta$  7.70 (m, 4H), 7.48–7.41 (m, 6H), 6.24–6.15 (dd, 1H,  $J=15.0$ , 10.2 Hz), 5.90–5.82 (m, 2H), 5.77 (d, 1H,  $J=10.2$  Hz), 5.63–5.54 (dd, 1H,  $J=14.8$ , 7.3 Hz), 5.51 (s, 1H), 5.51–5.43 (dd, 1H,  $J=15.3$ , 7.8 Hz), 5.17–5.09 (dd, 1H,  $J=14.2$ , 6.9 Hz), 3.73 (d, 1H,

$J=7.3$  Hz), 2.38 (m, 1H), 2.05 (m, 1H), 1.94 (m, 1H), 1.71 (s, 3H), 1.62 (m, 1H), 1.35–1.26 (m, 2H), 1.20 (s, 3H), 1.12 (s, 9H), 0.99 (d, 3H,  $J=6.9$  Hz), 0.95 (d, 3H,  $J=6.6$  Hz), 0.86 (t, 3H,  $J=7.1$  Hz).

The coupling product (22.3 mg, 37.0  $\mu$ mol) was dissolved in THF (373  $\mu$ L) and treated with HF-pyridine (200  $\mu$ L). After stirring for 24 h at room temperature, the resulting mixture was filtered through a pad of silica gel and concentrated in vacuo. Flash chromatography (4:1 hexanes/EtOAc) afforded the C5-epimer (**24**) (11.2 mg, 84%) as a colorless oil.  $[\alpha]_D^{27} +46.0$  (c 1.12, CHCl<sub>3</sub>); IR (KBr) 3566, 2962, 2924, 2860, 2360, 2342, 1771, 1750, 1717, 1699, 1684, 1653, 1636, 1558, 1540, 1521, 1507, 1489, 1457, 1418, 1396, 1203, 1130, 1064, 991  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (600 MHz, CDCl<sub>3</sub>) enol  $\delta$  6.27 (dd, 1H,  $J=15.3$ , 10.5 Hz), 6.18 (dd, 1H,  $J=15.0$ , 10.8 Hz), 6.13 (s, 1H), 6.01 (dd, 1H,  $J=15.0$ , 10.5 Hz), 5.76 (d, 1H,  $J=11.0$  Hz), 5.65 (dd, 1H,  $J=15.0$ , 8.5 Hz), 5.55–5.43 (m, 2H), 4.08 (d, 1H,  $J=8.0$  Hz), 2.45–2.39 (m, 1H), 2.15–1.92 (m, 3H), 1.71 (s, 3H), 1.46 (s, 3H), 1.32 (m, 2H), 0.99 (d, 3H,  $J=6.5$  Hz), 0.97 (d, 3H,  $J=6.5$  Hz), 0.86 (t, 3H,  $J=7.4$  Hz); ketone  $\delta$  6.27 (dd, 1H,  $J=15.3$ , 10.5 Hz), 6.18 (dd, 1H,  $J=15.0$ , 10.8 Hz), 6.01 (dd, 1H,  $J=15.0$ , 10.5 Hz), 5.76 (d, 1H,  $J=11.0$  Hz), 5.65 (dd, 1H,  $J=15.0$ , 8.5 Hz), 5.55–5.43 (m, 2H), 4.06 (d, 1H,  $J=8.0$  Hz), 3.07 (d, 1H,  $J=18.6$  Hz), 2.51 (d, 1H,  $J=18.6$  Hz), 2.45–2.39 (m, 1H), 2.15–1.92 (m, 3H), 1.71 (s, 3H), 1.52 (s, 3H), 1.32 (m, 2H), 0.99 (d, 3H,  $J=6.5$  Hz), 0.97 (d, 3H,  $J=6.5$  Hz), 0.86 (t, 3H,  $J=7.4$  Hz);  $^{13}\text{C}$  NMR (150 MHz, CDCl<sub>3</sub>) as a keto-enol mixture,  $\delta$  191.9, 160.7, 143.9, 142.9, 138.7, 138.6, 137.4, 135.4, 134.0, 133.8, 126.9, 126.7, 126.6, 125.9, 125.2, 124.7, 120.9, 87.3, 83.3, 78.1, 77.4, 47.4, 47.3, 43.8, 38.6, 34.8, 29.8, 29.7, 23.4, 20.2, 19.7, 19.5, 16.5, 11.8; HRMS (FAB, *m*-NBA)  $[\text{M}+\text{Na}]^+$  calcd for C<sub>22</sub>H<sub>32</sub>O<sub>4</sub>Na: 383.2198, found: 383.2195.

#### 4.4.14. (*S*)-5-[(*R*)-1-Hydroxyprop-2-ynyl]-5-methylfuran-2(5H)-one (**39**)

To a solution of **14** (228 mg, 0.932 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (9.3 mL) were added TEMPO (2.90 mg, 18.7  $\mu$ mol) and trichloroisocyanuric acid (217 mg, 0.932 mmol) at 0 °C. After stirring for 1 h, the resulting mixture was filtered through a pad of Celite and the filtrate was washed with a saturated aqueous NaHCO<sub>3</sub> solution. The organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. This crude aldehyde was employed in the next reaction without further purification.

To a solution of (CF<sub>3</sub>CH<sub>2</sub>O)<sub>2</sub>P(O)CH<sub>2</sub>CO<sub>2</sub>Me (400  $\mu$ L, 1.86 mmol) was added LHMDS (1.60 mL, 1.60 mmol) at 0 °C. After 30 min, a solution of the crude aldehyde was added dropwise to the resulting mixture at 0 °C. The reaction mixture was stirred for 10 min, quenched with saturated aqueous NH<sub>4</sub>Cl solution, and extracted with EtOAc. The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. Flash chromatography (40:1 hexanes/EtOAc) afforded the corresponding  $\alpha,\beta$ -unsaturated lactone (139 mg, 56% for 2 steps) as a colorless oil.  $[\alpha]_D^{23} -175.9$  (c 0.5, CHCl<sub>3</sub>); IR (KBr) 2945, 2864, 1768, 1254, 1113, 976, 843, 783, 675  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.46 (d, 1H,  $J=5.7$  Hz), 6.12 (d, 1H,  $J=5.7$  Hz), 4.43 (d, 1H,  $J=2.2$  Hz), 2.54 (d, 1H,  $J=2.2$  Hz), 1.57 (s, 3H), 0.87 (s, 9H), 0.14 (s, 3H), 0.09 (s, 3H);  $^{13}\text{C}$  NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  172.0, 156.9, 122.5, 89.7, 81.1, 75.1, 66.6, 25.5, 19.8, 18.0, -5.1, -5.4; HRMS (FAB, *m*-NBA)  $[\text{M}+\text{H}]^+$  calcd for C<sub>14</sub>H<sub>23</sub>O<sub>3</sub>Si: 267.1416, found: 267.1418.

A solution of the  $\alpha,\beta$ -unsaturated lactone (139 mg, 0.524 mmol) in THF (5.2 mL) was treated with HF-pyridine (1.5 mL) and stirred for 12 h at room temperature. The resulting mixture was filtered through a pad of silica gel and concentrated in vacuo. Flash chromatography (2:1 hexanes/EtOAc) afforded **39** (79.0 mg, 99%) as a colorless oil.  $[\alpha]_D^{24} -142.0$  (c 0.5, CHCl<sub>3</sub>); IR (KBr) 3543, 3300, 3251, 3111, 2993, 2933, 2885, 2121, 1720, 1641, 1444, 1390, 1308, 1238, 1122, 1059, 974, 895, 825, 696, 573, 534, 422, 409, 401  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.50 (d, 1H,  $J=5.7$  Hz), 6.16 (d, 1H,  $J=5.7$  Hz), 4.52 (dd, 1H,  $J=2.2$ , 6.2 Hz), 3.12 (br s, 1H), 2.58 (d, 1H,  $J=2.2$  Hz), 1.59 (s, 3H);  $^{13}\text{C}$  NMR (150 MHz, CDCl<sub>3</sub>)  $\delta$  172.2, 156.7,

122.7, 89.7, 79.8, 76.0, 65.9, 20.0; HRMS (FAB, *m*-NBA)  $[\text{M}+\text{H}]^+$  calcd for C<sub>8</sub>H<sub>9</sub>O<sub>3</sub>: 153.0552, found: 153.0553.

#### 4.4.15. (*S*)-5-[(*R,E*)-1-Hydroxy-3-(tributylstannyl)allyl]-5-methylfuran-2(5H)-one (**40**)

To a solution of **39** (79.0 mg, 0.52 mmol) and PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (10.7 mg, 26.0  $\mu$ mol) in THF (5.2 mL) was added dropwise Bu<sub>3</sub>SnH (420  $\mu$ L, 1.56 mmol) at room temperature. After 10 min, the resulting mixture was quenched with H<sub>2</sub>O and extracted with EtOAc. The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. Flash chromatography (5:1 hexanes/EtOAc) afforded **40** (157 mg, 68%) as a colorless oil.  $[\alpha]_D^{24} -35.0$  (c 0.5, CHCl<sub>3</sub>); IR (KBr) 3458, 2920, 2858, 1753, 1458, 1377, 1288, 1242, 1176, 1107, 999, 960, 877, 822, 683  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.42 (d, 1H,  $J=5.8$  Hz), 6.38 (dd, 1H,  $J=19.2$ , 1.5 Hz), 6.08 (d, 1H,  $J=5.8$  Hz), 6.01 (dd, 1H,  $J=19.2$ , 5.3 Hz), 4.19 (m, 1H), 2.33 (br d, 1H,  $J=5.1$  Hz), 1.76–1.44 (m, 6H), 1.44 (s, 3H), 1.42–1.24 (m, 6H), 0.92–0.86 (m, 15H);  $^{13}\text{C}$  NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  172.4, 158.4, 143.6, 133.2, 121.7, 90.3, 77.8, 29.0, 27.2, 19.7, 13.6, 9.5; HRMS (FAB, *m*-NBA)  $[\text{M}+\text{H}]^+$  calcd for C<sub>20</sub>H<sub>37</sub>O<sub>3</sub>Sn: 445.1765, found: 445.1769.

#### 4.4.16. 2-Dehydroxy- $\alpha,\beta$ -unsaturated lactone (**25**)

To a solution of **40** (89.7 mg, 0.202 mmol) in NMP (2.00 mL) were added **4** (83.5 mg, 0.263 mmol) and PdCl<sub>2</sub>(MeCN)<sub>2</sub> (5.20 mg, 20.6  $\mu$ mol). After stirring for 1.5 h at 50 °C, the reaction mixture was quenched with H<sub>2</sub>O and extracted with EtOAc. The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. Flash chromatography (3:1 hexanes/EtOAc) afforded the 2-dehydroxy- $\alpha,\beta$ -unsaturated lactone (**25**) (50.9 mg, 70%) as a colorless oil.  $[\alpha]_D^{27} -8.5$  (c 2.1, CHCl<sub>3</sub>); IR (KBr) 3446, 2961, 2924, 2872, 2360, 1750, 1653, 1558, 1540, 1507, 1488, 1456, 1376, 1237, 1110, 992, 966, 818  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.40 (d, 1H,  $J=6.0$  Hz), 6.30 (dd, 1H,  $J=15.2$ , 10.5 Hz), 6.17 (dd, 1H,  $J=15.0$ , 11.08 Hz), 6.09 (d, 1H,  $J=6.0$  Hz), 6.00 (dd, 1H,  $J=15.2$ , 10.5 Hz), 5.76 (d, 1H,  $J=10.9$  Hz), 5.69 (dd, 1H,  $J=15.2$ , 7.3 Hz), 5.54 (dd, 1H,  $J=15.2$ , 6.6 Hz), 5.45 (dd, 1H,  $J=15.0$ , 7.7 Hz), 4.25 (d, 1H,  $J=6.7$  Hz), 2.45–2.37 (m, 1H), 2.11–2.03 (m, 1H), 1.96 (dd, 2H,  $J=13.4$ , 7.8 Hz), 1.70 (s, 3H), 1.46 (s, 3H), 1.35–1.29 (m, 2H), 0.99 (d, 3H,  $J=6.8$  Hz), 0.97 (d, 3H,  $J=6.7$  Hz), 0.86 (t, 3H,  $J=7.4$  Hz);  $^{13}\text{C}$  NMR (150 MHz, CDCl<sub>3</sub>)  $\delta$  172.3, 158.0, 142.8, 138.7, 134.7, 134.0, 126.9, 126.8, 126.2, 124.7, 121.9, 90.6, 75.7, 47.4, 38.6, 34.8, 29.8, 20.2, 20.1, 19.6, 16.5, 11.8; HRMS (FAB, *m*-NBA)  $[\text{M}+\text{Na}]^+$  calcd for C<sub>22</sub>H<sub>32</sub>O<sub>3</sub>Na: 367.2249, found: 367.2250.

## Acknowledgements

This study was supported in part by a grant from the 21st Century COE Program, Ministry of Education, Culture, Sports, Science, and Technology, Japan. We thank Ms. N. Sato (Kitasato University) for kindly measuring NMR spectra. T.N. acknowledges a Kitasato University research grant for young researchers.

## References and notes

- Omura, S.; Miyadera, H.; Ui, H.; Shiomi, K.; Yamaguchi, Y.; Masuma, R.; Nagamitsu, T.; Takano, D.; Sunazuka, T.; Harder, A.; Kölbl, H.; Namikoshi, M.; Miyoshi, H.; Sakamoto, K.; Kita, K. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98*, 60–62.
- Ui, H.; Shiomi, K.; Yamaguchi, Y.; Masuma, R.; Nagamitsu, T.; Takano, D.; Sunazuka, T.; Namikoshi, M.; Omura, S. *J. Antibiot.* **2001**, *54*, 234–238.
- Takano, D.; Nagamitsu, T.; Ui, H.; Yamaguchi, Y.; Shiomi, K.; Masuma, R.; Kuwajima, I.; Omura, S. *Tetrahedron Lett.* **2001**, *42*, 3017–3020.
- Takano, D.; Nagamitsu, T.; Ui, H.; Shiomi, K.; Yamaguchi, Y.; Masuma, R.; Kuwajima, I.; Omura, S. *Org. Lett.* **2001**, *3*, 2289–2291.
- Shiomi, K.; Ui, H.; Suzuki, H.; Hatano, H.; Nagamitsu, T.; Takano, D.; Miyadera, H.; Kita, K.; Harder, A.; Tomoda, H.; Omura, S. *J. Antibiot.* **2005**, *58*, 50–55.
- Nagamitsu, T.; Takano, D.; Shiomi, K.; Ui, H.; Yamaguchi, Y.; Masuma, R.; Harigaya, Y.; Kuwajima, I.; Omura, S. *Tetrahedron Lett.* **2003**, *44*, 6441–6444.
- Nakamura, E. *Tetrahedron Lett.* **1981**, *22*, 663–666.
- Katsuki, T.; Sharpless, K. B. *J. Am. Chem. Soc.* **1980**, *102*, 5974–5976.

9. (a) Crispino, G. A.; Jeong, K. S.; Kolb, H. C.; Wang, Z. M.; Xu, D.; Sharpless, K. B. *J. Org. Chem.* **1993**, *58*, 3785–3786; (b) Andersson, P. G.; Sharpless, K. B. *J. Am. Chem. Soc.* **1993**, *115*, 7047–7048; (c) Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B. *Chem. Rev.* **1994**, *94*, 2483–2547.
10. Corey, E. J.; Guzman-Perez, A.; Noe, M. C. *J. Am. Chem. Soc.* **1995**, *117*, 10805–10816.
11. Ishihara, K.; Karumi, Y.; Kubota, M.; Yamamoto, H. *Synlett* **1996**, 839–841.
12. Dess, D. B.; Martin, J. C. *J. Org. Chem.* **1983**, *48*, 4155–4156.
13. Yadav, J. S.; Deshpande, P. K.; Sharma, G. V. M. *Tetrahedron* **1990**, *46*, 7033–7046.
14. (a) Anelli, P. L.; Biffi, C.; Montanari, F.; Quici, S. *J. Org. Chem.* **1987**, *52*, 2559–2562; (b) De Luca, L.; Giacomelli, G.; Porcheddu, A. *Org. Lett.* **2001**, *3*, 3041–3043.
15. Blanchette, M. A.; Choy, W.; Davis, J. T.; Essenfeld, A. P.; Masamune, S.; Roush, W. R.; Sakai, T. *Tetrahedron Lett.* **1984**, *25*, 2183–2186.
16. Kikukawa, K.; Umekawa, H.; Wada, F.; Matsuda, T. *Chem. Lett.* **1988**, 881–884.
17. (a) Stille, J. K.; Groh, B. L. *J. Am. Chem. Soc.* **1987**, *109*, 813–817; (b) Stille, J. K. *Angew. Chem., Int. Ed. Engl.* **1986**, *25*, 508–524; (c) Farina, V.; Krishnamurthy, V.; Scott, W. J. *Org. React.* **1997**, *50*, 1–652.
18. (a) Srogl, J.; Allred, G. D.; Liebeskind, L. S. *J. Am. Chem. Soc.* **1997**, *119*, 12376–12377; (b) Smith, A. B., III; Ott, G. R. *J. Am. Chem. Soc.* **1998**, *120*, 3935–3948.
19. Zhang, H. X.; Guibé, F.; Balavoine, G. J. *J. Org. Chem.* **1990**, *55*, 1857–1867.
20. Nishikawa, T.; Shibuya, S.; Hosokawa, S.; Isobe, M. *Synlett* **1994**, 485–486.
21. Still, W. C.; Gennari, C. *Tetrahedron Lett.* **1983**, *24*, 4405–4408.